Vaxcyte, Inc.

56.63 USD
-0.04 (-0.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Vaxcyte, Inc. stock is up 17.88% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 1 PUT, 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
27 Oct 17:21 17 Nov, 2023 45.00 PUT 200 30
17 Nov 15:47 19 Jan, 2024 55.00 CALL 233 10

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.